Original articleUltraviolet Radiation Exposure and the Risk of Herpes Zoster in Three Prospective Cohort Studies
Section snippets
Study Design and Population
The HPFS began in 1986 and enrolled 51,529 male health professionals aged 40 to 75 years. The NHS began in 1976 and enrolled 121,700 female registered nurses aged 30 to 55 years. The NHS II began in 1989 and enrolled 116,430 female registered nurses aged 25 to 42 years. In all 3 ongoing cohort studies, participants are followed via biennial questionnaires on medical and lifestyle information. The follow-up time has exceeded 90% of eligible person-time in all 3 studies. Three large, long-term,
Results
Among 205,756 participants, the mean age was 52 years in the HPFS, 62 years in the NHS, and 36 years in the NHS II at baseline. The baseline characteristics of participants according to ambient UVR exposure status are presented in Table 1 and Supplemental Tables 1-3 (available online at http://www.mayoclinicproceedings.org). In all 3 cohorts, the characteristics of participants, including age, physical activity, and comorbidities, were similar across the quintiles of UVR exposure groups. Among
Discussion
We examined the association between UVR exposure and the risk of HZ in 3 large cohorts of men and women. Recent ambient UVR exposure was associated with a higher risk of HZ in men in the HPFS but not in women in the NHS and NHS II. In addition, skin reaction to prolonged sunlight was associated with a higher risk of HZ in men in the HPFS and in younger women in the NHS II. A higher lifetime number of severe or blistering sunburns was associated with an increased risk of HZ in all 3 cohorts.
This
Conclusion
Ambient UVR exposure was associated with a higher risk of HZ in men in the HPFS but not in women in the NHS and NHS II. A higher lifetime number of severe sunburns was associated with a modest increased risk of HZ in all 3 cohorts. Our findings highlight the importance of future research on long-term immunomodulating effects from overexposure to UVR.
Acknowledgments
We thank Elaine Coughlin-Gifford, MS, for her support with statistical programming. We also thank the participants and staff of the Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals Follow-up Study.
References (34)
- et al.
A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction
Mayo Clin Proc
(2007) - et al.
What does epidemiology tell us about risk factors for herpes zoster?
Lancet Infect Dis
(2004) - et al.
Risk factors for herpes zoster: a systematic review and meta-analysis
Mayo Clin Proc
(2017) - et al.
Family history and herpes zoster risk in the era of shingles vaccination
J Clin Virol
(2011) - et al.
Temporal trends in incidence rates of herpes zoster among patients treated in primary care centers in Madrid (Spain), 2005-2012
J Infect
(2014) - et al.
Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis
Am J Clin Nutr
(2010) - et al.
UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide
J Invest Dermatol
(2008) The nature of herpes zoster: a long-term study and a new hypothesis
Proc R Soc Med
(1965)- et al.
Quantification of risk factors for herpes zoster: population based case-control study
BMJ
(2014) - et al.
Examination of links between herpes zoster incidence and childhood varicella vaccination
Ann Intern Med
(2013)
Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture
J Med Virol
Varicella vaccination alters the chronological trends of herpes zoster and varicella
PLoS One
Increasing incidence of herpes zoster over a 60-year period from a population-based study
Clin Infect Dis
Increasing trends of herpes zoster in Australia
PLoS One
The effect of ultraviolet radiation on human viral infections
Photochem Photobiol
The role of solar ultraviolet irradiation in zoster
Epidemiol Infect
Varicella-zoster virus in Perth, Western Australia: seasonality and reactivation
PLoS One
Cited by (0)
For editorial comment, see page 207
Grant Support: The work was supported by grants UM1 CA186107, UM1 CA176726, UM1 CA167552, and DK091417 from the National Institutes of Health.
Potential Competing Interests: Dr VoPham has received grant T32 CA009001 from the National Cancer Institute. Dr S.G. Curhan has received consultancy fees from Decibel Therapeutics (outside the submitted work). Dr G.C. Curhan has received a K24 grant from the National Institutes of Health. He has also received consultancy fees from Allena Pharmaceuticals, Shire, AstraZeneca, RenalGuard, Merck, and Decibel Therapeutics; receives royalties from UpToDate; owns stocks in Allena Pharmaceuticals; and was Editor-in-Chief of the Clinical Journal of American Society of Nephrology (outside the submitted work). The other authors report no competing interests.